Source: CureToday articles
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
Recent Content
- What Should Patients with Multiple Myeloma Know After ASCO 2025?
- A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
- High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma
- Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
- Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
- You Are Not Alone While Building a Support Team During Cancer Care
- Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
- When Treatment Ends, Support Shouldn’t Stop in Cancer Care
- Sequencing Strategies and the Role of Combination Therapy
- Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis